Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.

AIMS To determine the frequencies of the genotypes of CYP3A5 and MDR1 and to examine the influence of the polymorphisms of these genes on tacrolimus pharmacokinetics in the Korean population. METHODS Twenty-nine healthy Koreans who participated in the previous tacrolimus pharmacokinetic study were genotyped for CYP3A4*1B, CYP3A5*3, MDR1 c.1236C-->T, MDR1 c.2677G-->A/T and MDR1 c.3435C-->T. The relationship between the genotypes so obtained and tacrolimus pharmacokinetics observed in the previous study was examined. RESULTS No subject in this study had the CYP3A4*1B variant. The observed frequencies of CYP3A5*1/*1, *1/*3, and *3/*3 were 0.069 [confidence interval (CI) -0.023, 0.161], 0.483 (CI 0.301, 0.665) and 0.448 (CI 0.267, 0.629), respectively. AUC(0-infinity) for the CYP3A5*1/*1 or *1/*3 genotype was 131.5 +/- 44.8 ng h ml(-1) (CI 109.6, 153.5), which was much lower compared with the CYP3A5*3/*3 genotype of 323.8 +/- 129.3 ng h ml(-1) (CI 253.5, 394.1) (P = 2.063E-07). Similarly, C(max) for the CYP3A5*1/*1 or *1/*3 genotype was 11.8 +/- 3.4 ng ml(-1) (CI 10.1, 13.5), which was also much lower compared with the CYP3A5*3/*3 genotype of 24.4 +/- 12.3 ng ml(-1) (CI 17.8, 31.1) (P = 0.0001). However, there was no significant difference in tacrolimus pharmacokinetics among the MDR1 diplotypes of CGC-CGC, CGC-TTT, CGC-TGC, TTT-TGC or TTT-TTT (P = 0.2486). CONCLUSIONS This study shows that the CYP3A5*3 genetic polymorphisms may be associated with the individual difference in tacrolimus pharmacokinetics. An individualized dosage regimen design incorporating such genetic information would help increase clinical efficacy of the drug while reducing adverse drug reactions.

[1]  P. Beaune,et al.  Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. , 2003, Journal of the American Society of Nephrology : JASN.

[2]  J. Verweij,et al.  Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients , 2004, Clinical Cancer Research.

[3]  G. Small.  Neuroimaging as a Diagnostic Tool in Dementia with Lewy Bodies , 2003, Dementia and Geriatric Cognitive Disorders.

[4]  K. Budde,et al.  MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. , 2004, British journal of clinical pharmacology.

[5]  T. Sakaeda,et al.  Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. , 2003, Pharmacogenomics.

[6]  S. Keam,et al.  Tacrolimus: a further update of its use in the management of organ transplantation. , 2003, Drugs.

[7]  D. Hesselink,et al.  The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? , 2005, Pharmacogenomics.

[8]  B. Meibohm,et al.  Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. , 2004, International journal of clinical pharmacology and therapeutics.

[9]  First Mr.  Tacrolimus based immunosuppression. , 2004 .

[10]  B. Griffith,et al.  Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism , 2004, Journal of clinical pharmacology.

[11]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  D. Holt,et al.  Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians , 2005, Transplantation.

[13]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[14]  J. Squifflet,et al.  The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. , 2004, Pharmacogenetics.

[15]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[16]  U. Brinkmann,et al.  Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.

[17]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[18]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[19]  U. Christians,et al.  The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups , 2001, Clinical pharmacology and therapeutics.

[20]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.

[21]  V. Haufroida,et al.  The effect of CYP 3 A 5 and MDR 1 ( ABCB 1 ) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients , 2004 .

[22]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[23]  K. Kwon,et al.  A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. , 2007, Clinical therapeutics.

[24]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[25]  R. Ho,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function , 2004 .

[26]  N. Kamatani,et al.  Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population , 2003, Human mutation.

[27]  Haiyang Xie,et al.  Influence of CYP3A5 Gene Polymorphisms of Donor Rather than Recipient to Tacrolimus Individual Dose Requirement in Liver Transplantation , 2006, Transplantation.

[28]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[29]  B. Vinet,et al.  Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.

[30]  C. Felipe,et al.  The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring , 2002, Clinical transplantation.

[31]  R. Ho,et al.  The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. , 2004, Current drug metabolism.

[32]  David B. Witonsky,et al.  CYP3A variation and the evolution of salt-sensitivity variants. , 2004, American journal of human genetics.